Abstract
Phosphodiesterase 2 (PDE2) is a ubiquitous enzyme whose major role is to hydrolyze the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the central nervous system, pharmacological inhibition of PDE2 results in boosted cAMP and/or cGMP signaling, which is responsible for series of changes in protein expression relevant to psychiatric and learning and memory disorders, such as depression, anxiety, and cognition deficits in Alzheimer’s disease. In the periphery, inhibition of PDE2 exhibits beneficial effects in the diseased cardiovascular system, the respiratory system, skeletal muscles and Candida albicans-caused systemic infections. Even though blood-brain barrier penetration properties and selectivity of currently available PDE2 inhibitors have hindered them from entering clinical trials, PDE2 is still of great potential therapeutic values in different categories of diseases, and there is demand for development of new generation drugs targeting PDE2 for treatment of diseases in central nervous and peripheral systems.
Keywords: Phosphodiesterase 2 (PDE2), cyclic AMP (cAMP), cyclic GMP (cGMP), emotion, cognition, cardiovascular health, respiratory health, systemic infection.
Current Pharmaceutical Design
Title:The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Volume: 21 Issue: 3
Author(s): Chong Zhang, Yingcong Yu, Lina Ruan, Chuang Wang, Jianchun Pan, Jonathan Klabnik, Lindsay Lueptow, Han-Ting Zhang, James M. O’Donnell and Ying Xu
Affiliation:
Keywords: Phosphodiesterase 2 (PDE2), cyclic AMP (cAMP), cyclic GMP (cGMP), emotion, cognition, cardiovascular health, respiratory health, systemic infection.
Abstract: Phosphodiesterase 2 (PDE2) is a ubiquitous enzyme whose major role is to hydrolyze the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the central nervous system, pharmacological inhibition of PDE2 results in boosted cAMP and/or cGMP signaling, which is responsible for series of changes in protein expression relevant to psychiatric and learning and memory disorders, such as depression, anxiety, and cognition deficits in Alzheimer’s disease. In the periphery, inhibition of PDE2 exhibits beneficial effects in the diseased cardiovascular system, the respiratory system, skeletal muscles and Candida albicans-caused systemic infections. Even though blood-brain barrier penetration properties and selectivity of currently available PDE2 inhibitors have hindered them from entering clinical trials, PDE2 is still of great potential therapeutic values in different categories of diseases, and there is demand for development of new generation drugs targeting PDE2 for treatment of diseases in central nervous and peripheral systems.
Export Options
About this article
Cite this article as:
Zhang Chong, Yu Yingcong, Ruan Lina, Wang Chuang, Pan Jianchun, Klabnik Jonathan, Lueptow Lindsay, Zhang Han-Ting, O’Donnell James M. and Xu Ying, The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems, Current Pharmaceutical Design 2015; 21 (3) . https://dx.doi.org/10.2174/1381612820666140826115245
DOI https://dx.doi.org/10.2174/1381612820666140826115245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Effects of Perfluorocarbon Dodecafluoropentane (NVX-108) on Cerebral Microvasculature in the Healthy Rat
Current Drug Discovery Technologies New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain
Current Molecular Medicine The Alzheimer Pandemic: Is Paracetamol to Blame?
Inflammation & Allergy - Drug Targets (Discontinued) The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines
Current Stem Cell Research & Therapy Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Preface [Hot Topic: Cannabinoid Receptors (Guest Editor: Maria L. Lopez-Rodriguez)]
Current Medicinal Chemistry - Central Nervous System Agents Editorial [ The Wide Roles of Cytokines During Evolution Executive Editors: M. de Eguileor and E. Ottaviani ]
Current Pharmaceutical Design Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments
Current Pharmaceutical Design Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued)